Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes

Pharmacology

Volumn 79, Issue 3, 2007, Pages 171-183

  Bishnoi, Mahendra ^a   Chopra, Kanwaljit ^a   Kulkarni, Shrinivas K ^a,b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Adenosinergic receptor system; Dipyridamole; Neuroleptics; Vacuous chewing movements

Indexed keywords

ADENOSINE; CATALASE; DIPYRIDAMOLE; DOPAMINE; GLUTATHIONE; HALOPERIDOL; NIMODIPINE; NORADRENALIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; BRAIN DAMAGE; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; LIPID PEROXIDATION; LOCOMOTION; MALE; MASTICATION; MAZE TEST; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; STEREOTYPY; TARDIVE DYSKINESIA; TURNOVER TIME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CATALASE; DIPYRIDAMOLE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; EXTRACELLULAR SPACE; GLUTATHIONE; HALOPERIDOL; INJECTIONS, INTRAPERITONEAL; LIPID PEROXIDATION; MALE; MAZE LEARNING; MOTOR ACTIVITY; NIMODIPINE; NOREPINEPHRINE; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P1; RETENTION (PSYCHOLOGY); SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 34247350350     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100924     Document Type: Article

References (39)

1. Rupp A, Keith SJ: The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993;16:413-423.
2. Synder SL, Banerjee SP, Yamamura H, Greenberg D: Drugs neurotransmitters and schizophrenia. Science 1974;184:1243-1253.
3. Casey DE: Tardive dyskinesia: pathophysiology and animal models. I. J Psychiatry 2000;61:5-9.
4. Naidu PS, Singh A, Kulkarni SK: Quercetin, a bioflavonoid attenuated haloperidol-induced orofacial dyskinesia. Neuropharmacology 2003;44:1100-1106.
5. Burger MBE, Fachineto R, Callegari L, Paixao MW, Braga AL, Rocha JBT: Effect of age on reserpine-induced orofacial dyskinesia possible protection of diphenyl diselenide. Brain Res Bull 2004;64:339-345.
6. Gerlach J, Casey DE: Tardive dyskinesia. Acta Psychiatr Scand 1988;77:369-378.
7. Lohr JB: Oxygen free radicals and neuropsychiatric illness. Arch Gen Psychiatry 1991;48:1097-1106.
8. Lohr JB, Kuczenski R, Niculescu AB: Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003;17:47-62.
9. Naidu PS, Kulkarni SK: Excitatory mechanisms in neuroleptic-induced vacuous chewing movements: possible involvement of calcium and nitric oxide. Behav Pharmacol 2001;12:209-216.
10. Tsai GC, Golf DC, Chang RW, Flood J, Baer L, Coyle JT: Markers of glutamatergic transmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998;155:1207-1213.
11. Ribeiro JA, Sebastiao AM, Mendonca AD: Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 2003;68:377-392.
12. Stone TW: Adenosine, neurodegeneration and neuroprotection. Neurol Res 2005;27:161-168.
13. Burger MBE, Fachineto R, Zeni G, Rocha JBT: Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav 2005;81:608-615.
14. Torres IL, Bonan CD, Crema L, De Leon Nunes M, Battastini AM, Sarkis JJ, Dalmaz C, Ferreira MB: Effect of drugs active at adenosine receptors upon chronic stress-induced hyperalgesia in rats. Eur J Pharmacol 2003;481:197-201.
15. Rice AM, Fain JN, Rivkees SA: A1 adenosine receptor activation increases adipocyte leptin secretion. Endocrinology 2000;141:1442-1445.
16. Deckert J, Gleiter CH: Adenosine - an endogenous neuroprotective metabolite and neuromodulator. J Neural Transm Suppl 1994;43:23-31.
17. Reddy DS, Kulkarni SK: Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging and dizocilpine-induced learning impairment. Brain Res 1998;799:215-219.
18. Itoh J, Nabeshima T, Kameyama T: Utility of an elevated plus maze for dissociation of amnesic and behavioural effects of drugs in mice. Eur J Pharmacol 1994;1991:71-76.
19. Kulkarni SK: Handbook of Experimental Pharmacology, ed 3. Delhi, Vallabh Prakashan, 1999, p 119.
20. Wills ED: Mechanism of lipid peroxide formation in animal tissues. Biochem J 1966;99:667-676.
21. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
22. Kono Y: Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys 1978;186:189-195.
23. Luck H: Catalase Spectrophotometric Method. Methods in Enzymatic Analysis. New York, Academic Press, 1963.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
25. Church WH: Column chromatography analysis of brain tissue: an advanced laboratory exercise for neuroscience majors. J Undergrad Neurosci Educ 2005;3:A36-A41.
26. Xu K, Bastia E, Schwarzschild M: Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol Ther 2005;105:267-310.
27. Thaker GK, Nguyen AJ, Tamminga CA: Increased saccadic distractibility in tardive dyskinesia: functional evidence for subcortical GABA dysfunction. Biol Psychiatry 1988;1:49-59.
28. Dawson R, Beal MF, Bondy SC, Monte D, Isom GE: Excitotoxins, aging and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxicol Appl Pharmacol 1995;134:1-17.
29. Andreassen OA, Jorgensen HA: Neurotoxicity associated with neuroleptic-induced oral dyskinesia in rats, implications for tardive dyskinesia. Prog Neurobiol 2000;65:525-531.
30. Mitchell IJ, Cooper MR, Griffiths MR, Cooper AJ: Acute administration of haloperidol induces apoptosis of neurons in the striatum and substantia nigra in the rat. Neuroscience 2002;109:89-99.
31. See RE, Lynch AM, Aravagiri M, Aravagiri CM, Owens MJ: Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin contents in rats. Brain Res 1995;704:202-209.
32. Marchese G, Casu MA, Ruiu S, Saba P, Gessa GL, Pani L: Subchronic administration with classical but not atypical anti-psychotics produces morphological changes in rat nigrostriatal dopaminergic neuron directly related to early onset vacuous chewing. Eur J Neurosci 2002;15:1187-1196.
33. MacGregor DG, Miller WJ, Stone TW: Mediation of neuroprotective action of R-phenyl isopropyl-adenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration. Br J Pharmacol 1993;110:470-476.
34. Lau YS, Mouradian MM: Protection against acute MPT-induced dopamine depletion in mice by adenosine. J Neurochem 1993;60:768-771.
35. Macgregor DG, Jones PA, Maxwel WL: Prevention by a purine analogue of kainate-induced neuropathology in rat hippocampus. Brain Res 1996;725:115-120.
36. Stone TW, Jones PA, Smith RA: Neuroprotection by A2A receptor antagonists. Drug Dev Res 2001;52:323-330.
37. Lau YS, Petroske E, Meredith GE, Wang JQ: Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats. Neuropharmacology 2003;45:986-994.
38. 1-adrenoceptor binding following chronic haloperidol and clozapine administration in rat. Psychopharmacology 2004;172:196-201.
39. Bishnoi M, Chopra K, Kulkarni SK: Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 2006;552:55-66.